Clinical Trial

Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease

Study acronym: SSIPCKD
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. People with chronic kidney disease (CKD) often experience chronic inflammation and digestive symptoms that may affect their quality of life. This study aims to evaluate whether daily supplementation with a synbiotic (a combination of probiotics and prebiotics) can reduce inflammation and improve gastrointestinal symptoms in adults with chronic kidney disease (CKD) stages 3 to 5 who are not receiving dialysis. Participants will be randomly assigned to receive either a synbiotic containing Lactobacillus rhamnosus, Bifidobacterium longum, and agave fructans, or a placebo, for a total of 16 weeks. Blood tests will be performed to measure inflammation, and participants will complete questionnaires related to digestive symptoms, quality of life, and dietary habits. The information obtained from this study may help improve nutritional strategies and supportive care for people living with chronic kidney disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-18.
Trial Details
NCT Number NCT07430280
Lead Sponsor Centenario Hospital Miguel Hidalgo
Conditions Chronic Kidney Disease, Inflammation
Enrollment 100 participants
Start Date 2026-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27